Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa/b randomized double-blind placebo-controlled study of DDY391 in active moderate-to-severe psoriatic arthritis
CTR20263946Phase 2Active
- Sponsor
- Novartis
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of DDY391 in psoriatic arthritis (PsA), sponsored by Novartis. Started Oct 2026; status: active.
02
Drugs
DDY391
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on CTR20263946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263946.